Increasing Participation in NCI-Funded Clinical Trials at Winship Cancer Institute

增加对温希普癌症研究所 NCI 资助的临床试验的参与

• 批准号: 10721093
• 负责人: Jonathon B. Cohen
• 金额: $ 15.66万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-22 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10721093
• 关键词: Address; American College of Radiology Imaging Network; Award; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Communities; Community Outreach; Conduct Clinical Trials; Country; Data; Development; Disease; Early Therapeutic-Clinical Trials Network; Eastern Cooperative Oncology Group; Enrollment; Ensure; Funding; Future; Growth; Home; Improve Access; Institution; Lead; Leadership; Lymphoma; Malignant Neoplasms; Modality; Monitor; National Clinical Trials Network; Oncologist; Patient-Focused Outcomes; Patients; Persons; Positioning Attribute; Research; Research Personnel; Resources; Role; Safety; Series; Site; Specialist; Therapeutic Studies; Tumor Expansion; Universities; career; cohort; community engagement; experience; improved; improved outcome; innovation; interest; metropolitan; next generation; participant enrollment; programs; skills; standard of care; success; virtual; working group

PROJECT SUMMARY/ABSTRACT I have devoted my career to the improvement of outcomes for patients with lymphoma and have utilized my expertise to improve clinical trial conduct at my home institution and nationally. I have developed a sincere commitment to the success of NCI-funded clinical trials, which often address the most critical clinical questions and which consistently challenge the standard of care in order to improve patient outcomes nationwide. Winship Cancer Institute of Emory University is a National Clinical Trial Network Lead Academic Participating Site and boasts a robust clinical trial portfolio, enrolling roughly 1000 patients per year to therapeutic studies at multiple sites throughout metropolitan Atlanta. I am the co-director of the lymphoma disease program, leader of the lymphoma treatment modality working group, and chair of the Data Safety Monitoring Committee. In these roles I can impact clinical trials in my clinic and throughout the Cancer Center. I have also assumed leadership of trials through the ECOG-ACRIN lymphoma committee (PrE0404, A051201), have recently been appointed to represent ECOG-ACRIN’s lymphoma committee on a Real World Evidence Working Group, and am the co-chair of the lymphoma disease specific working group for Winship’s ETCTN consortium. As a result, I am well- positioned to significantly impact of the success of NCI-funded studies. I will utilize the resources of the R50 Research Specialist Award to improve NCI-funded clinical trials through improved access and accrual to NCTN and ETCTN trials in Atlanta and the state of Georgia by strengthening existing collaborations with oncologists throughout the state in association with Winship’s Office of Community Outreach and Engagement. This will include expansion of tumor boards and national programming, 1:1 in person and virtual communication with colleagues, and facilitation of opportunities to enroll patients in NCTN studies closer to their home communities. I will continue to develop a pipeline of junior investigators and trainees nationwide who are interested in clinical trials and will ensure they have access to NCTN and ETCTN support to support development of their own concepts. I will develop the next series of trials by utilizing my experience as a leader in Real World Evidence cohorts, both within ECOG-ACRIN and with colleagues throughout the country. I will continue growth of the NCTN and ETCTN at Winship and will ensure that colleagues continue to have innovative studies to which to enroll patients and have the skills needed to develop their own projects based on current and future clinical needs.

项目概要/摘要 我的职业生涯致力于改善淋巴瘤患者的治疗结果，并利用我的 为了改善我所在机构和全国的临床试验实施，我建立了真诚的专业知识。 致力于 NCI 资助的临床试验取得成功，这些试验通常解决最关键的临床问题 并不断挑战护理标准，以改善全国患者的治疗效果。 埃默里大学癌症研究所是国家临床试验网络牵头学术参与站点 拥有强大的临床试验组合，每年招募约 1000 名患者参加多个机构的治疗研究 我是淋巴瘤疾病项目的联合主任，也是该项目的领导者。 淋巴瘤治疗方式工作组和数据安全监测委员会主席。 我可以影响我的诊所和整个癌症中心的临床试验，我还担任试验的领导。 通过 ECOG-ACRIN 淋巴瘤委员会（PrE0404、A051201），最近被任命为 ECOG-ACRIN 淋巴瘤委员会真实世界证据工作组，并担任联合主席 Winship 的 ETCTN 联盟淋巴瘤疾病特定工作组的成员 因此，我很高兴—— 我将利用 R50 的资源对 NCI 资助的研究的成功产生重大影响。 研究专家奖旨在通过改善 NCTN 的获取和累积来改善 NCI 资助的临床试验 通过加强与肿瘤学家的现有合作，在亚特兰大和佐治亚州进行 ETCTN 试验 与 Winship 社区外展和参与办公室合作，在全州范围内开展工作。 包括扩大肿瘤委员会和国家规划，与以下人员进行 1:1 面对面和虚拟交流 同事们的帮助，并为患者有机会参加离他们的家乡社区更近的 NCTN 研究提供便利。 我将继续在全国范围内培养一批对临床感兴趣的初级研究者和实习生 试验并将确保他们能够获得 NCTN 和 ETCTN 支持以支持自己的开发 我将利用我作为现实世界证据领导者的经验来开发下一系列的试验。 我将继续与 ECOG-ACRIN 内部以及全国各地的同事一起发展。 Winship 的 NCTN 和 ETCTN 并将确保同事们继续进行创新研究 招募患者并具备根据当前和未来的临床开发自己的项目所需的技能 需要。